Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 4238 results
Second Genome secures $42.6m funding to expand microbiome discovery platform
Second Genome, a privately-held biopharmaceutical company developing novel medicines through innovative microbiome science, has closed an oversubscribed Series B investment round with $42.6m in financing.
Drug Research > Drug Discovery & Development > News
DalCor completes $150m financing to continue development of dalcetrapib in ACS
By PBR Staff Writer
DalCor Pharmaceuticals has wrapped up a private financing round valued at $150m to continue the development of dalcetrapib in genetically distinct patients with acute coronary syndrome (ACS).
Drug Research > Drug Discovery & Development > News
NanoAntibiotics acquires biotechnology firm LAT Pharma
NanoAntibiotics has acquired LAT Pharma LLC, of Chicago, IL, an early-stage biotechnology company developing novel medicines to treat life-threatening complications of liver cirrhosis.
Drug Research > Drug Discovery & Development > News
Sunny Pharmtech and Vitruvias partner to co-develop several high value generic drugs
Sunny Pharmtech and Vitruvias Therapeutics have signed two additional agreements to co-develop and market two additional high-value generic drugs.
Drug Research > Drug Discovery & Development > News
Heptares, Kymab partner to develop novel antibody therapeutics
By PBR Staff Writer
Heptares Therapeutics and Kymab have partnered to discover, develop and commercialize novel antibody therapeutics.
Drug Research > Drug Discovery & Development > News
WuXi AppTec acquires Crelux to improve structure-based drug discovery capabilities
WuXi AppTec has acquired Crelux, a structure based drug discovery provider based in Munich, Germany
Drug Research > Drug Discovery & Development > News
Transplant Genomics, Quark Pharmaceuticals form discovery and development collaboration
Transplant Genomics ("TGI") and Quark Pharmaceuticals announced their joint intent to pursue a discovery and development collaboration involving the use of TGI's TruGraf blood test in a Phase 3 clinical trial involving patients being treated for delayed graft function (DGF) with Quark's proprietary drug candidate QPI-1002.
Drug Research > Drug Discovery & Development > News
Cydan Development launches second orphan drug company
By PBR Staff Writer
Cydan Development has launched its second orphan drug firm, Imara, and raised $31m in a Series A round from a group of investors including Pfizer Venture Investments and New Enterprise Associates.
Drug Research > Drug Discovery & Development > News
AmpliPhi Biosciences ends exclusive channel collaboration with Intrexon
By PBR Staff Writer
AmpliPhi Biosciences has terminated its collaboration agreement with Intrexon which was signed in 2013 to develop new bacteriophage-based therapies for antibiotic resistant infections.
Drug Research > Drug Discovery & Development > News
Kala Pharmaceuticals raises $68m funding to advance eyedrop treatment
By PBR Staff Writer
Kala Pharmaceuticals has raised $68m in new funding to advance work on KPI-121 eye treatment.
Drug Research > Drug Discovery & Development > News
Karos advances development of KAR5585 into clinic to treat pulmonary arterial hypertension
Karos Pharmaceuticals has advanced its small molecule drug candidate, KAR5585, into the clinic.
Drug Research > Drug Discovery & Development > News
Immunovaccine, Leidos partner to develop Zika Virus vaccine candidate
Immunovaccine and Leidos will collaborate on developing a vaccine against the mosquito-borne Zika virus and infection, which may be linked to neurological birth defects.
Drug Research > Drug Discovery & Development > News
Juno, WuXi AppTec launch new cancer immunotherapies company in China
Juno Therapeutics and WuXi AppTec have started a new company in China to develop novel cell-based cancer immunotherapies.
Drug Research > Drug Discovery & Development > News
Incyte acquires rights from Lilly to develop Ruxolitinib to treat graft-versus-host disease
Incyte has acquired the rights to develop and commercialize ruxolitinib (Jakafi), its proprietary JAK1/JAK2 inhibitor, for graft-versus-host disease (GVHD) from Eli Lilly and Company.
Drug Research > Drug Discovery & Development > News
Johnson & Johnson to develop Tesaro’s prostate cancer candidate Niraparib
By PBR Staff Writer
Johnson & Johnson said it will invest $50m in Tesaro and license a potential prostate cancer treatment from the oncology-focused biopharmaceutical firm.
Drug Research > Drug Discovery & Development > News
91-105 of 4238 results